Karuna Therapeutics Inc. (KRTX) Prices 2.6M Share Offering at $96/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
After-Hours Movers 11/20: (XXII) (NUAN) (TIF) Higher; (OPTN) (LZB) (CUB) Lower (more...)
November 20, 2019 6:00 PM ESTAfter-Hours Movers
Optinose (NASDAQ: OPTN) 10.2% LOWER; announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an underwritten public offering.
La-Z-Boy (NYSE: LZB) 8.6% LOWER; reported Q2 EPS of $0.52, $0.02 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $447.2 million versus the consensus estimate of $454.39 million.
22nd Century Group (NYSE: XXII) 7.8% HIGHER; rebounds slightly after falling 43%... More
Karuna Therapeutics Inc. (KRTX) PT Raised to $134 at Wedbush
November 20, 2019 4:18 PM ESTWedbush analyst Liana Moussatos raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $134.00 (from $38.00) while maintaining a Outperform rating.
... MoreKaruna Therapeutics Inc. (KRTX) Climbs 30%
November 19, 2019 10:36 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Climbs 30%
... MoreKaruna Therapeutics Inc. (KRTX) Halted on LUDP
November 19, 2019 10:18 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP
... MorePre-Open 11/19: (MYOV) (MDCO) (VKTX) Higher (I) (KSS) (HD) Lower (more...)
November 19, 2019 9:13 AM ESTPre-Open Movers
Myovant Sciences (NYSE: MYOV) 65.8% HIGHER; announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. These results support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020 and future regulatory submissions in Europe and Japan.
Medicines Co. (NASDAQ:... More
